Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neurontin Settlement Of $430 Mil. Is High For Off-Label Case, Low For Pfizer

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer's $430 mil. Neurontin off-label promotion settlement is the equivalent of about nine weeks of U.S. sales of the anti-epileptic brand
Advertisement

Related Content

Schering-Plough Physician Payments May Be Next Target Of Federal Prosecutors
Schering-Plough Physician Payments May Be Next Target Of Federal Prosecutors
Pfizer Pregabalin Approved For Marketing In Europe; FDA Review Continues
Pfizer Pregabalin Approved For Marketing In Europe; FDA Review Continues
Senate Finance Committee Seeks Review Of Manufacturer Investigations By DOJ, HHS
Senate Finance Committee Seeks Review Of Manufacturer Investigations By DOJ, HHS
Teva, Ivax Move Closer To Marketing Generic Gabapentin; Neurontin Litigation Continues
Teva, Ivax Move Closer To Marketing Generic Gabapentin; Neurontin Litigation Continues

Topics

Advertisement
UsernamePublicRestriction

Register

PS059405

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel